Medical unmet needs

• 

  High mortality rate

  The most common 1 brain tumor (glial cell)

  Malignancy in Central Nervous System

  Average survival rate : 12-15 months, Survival rate for 5 years: less than 3-5%

  Mortality : within a year (50% of patients), within 3 years (90% of patients)

• 

  Lack of effective therapies

  Standard treatment : aggressive resection followed by radiation with temosolomide (TMZ)

  Median survival rate : Around 15-17 months

  Not complete resection due to Invasive growth, multiple lesions, etc., resistance, side effects, and recurrence

• 

  In need of new therapies

  Ad-TK alone: safety but low efficacy in Phase III

  Telomerase overexpressed in 85-90% (80% mutant Tert promoter), but tel length heterogeneity including GSCs; poor prognosis Tel inhibitor largely failed in Clinics

  Immune evasion Immune checkpoint inhibitor (side effects, combination treatment)